Adaptive Biotechnologies to Participate in Morgan Stanley Healthcare Conference

SEATTLE, Sept. 01, 2026 /CourierPR/ -- Adaptive Biotechnologies, a leading biotechnology firm focused on translating the adaptive immune system into clinical products for disease diagnosis and treatment, will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 15, 2026. The company's management team will engage in a fireside chat, scheduled for 1:50 p.m. Pacific Time / 4:50 p.m. Eastern Time.

Interested participants can access a live and archived webcast of the presentation on the company’s website, which is accessible through the “Investors” section at www.adaptivebiotech.com.

Adaptive Biotechnologies specializes in leveraging the adaptive immune system to diagnose and treat various diseases. The company’s proprietary immune medicine platform allows for the decoding of the vast genetics of the adaptive immune system, providing scale, precision, and speed. This platform is used to develop clinical diagnostics and minimal residual disease (MRD) products in collaboration with biopharmaceutical companies.

The company’s commercial products and clinical pipeline focus on the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Through its two business segments—Minimal Residual Disease and Immune Medicine—Adaptive Biotechnologies aims to develop tailored clinical products for individual patients.